ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s strong performance in the market look set to continue as investors react to yet another impressive report that affirms growth in the core business. Strong performance through continued growth of new prescribers on Nuplazid, a Parkinson disease treatment, all but affirms the company’s long term prospects.
Parkinson Treatment Sales
The biopharmaceutical company achieving a significant milestone in the development of late stage programs, also continues to trigger renewed investor interest in the stock. The acquisition of CerSci Therapeutics is another development that affirms its long-term prospects for expanding the pipeline of drugs.
Sales for the company’s lead Parkinson drug clocked highs of $120.6 million in the quarter, representing a 27% increase. ACADIA’s Nuplazid is the first, and only FDA approved medication for addressing hallucinations and delusions commonly associated with Parkinson disease.
In the first half of the year, ACADIA generated $200.2 million in Nuplazid sales representing a 36% year-over-year increase. The biopharmaceutical company is targeting CNS indications a label likely to boost the drug sales in the future.
Revenue for the nine months totaled $320.7 million compare to $240.8 million reported a year ago. Net loss widened to $84.7 million compared to $42 million a year ago. Buoyed by strong demand in the third quarter, ACADIA has updated its full-year guidance.
ACADIA Guidance
ACADIA expects Nuplazid net sales to clock highs of between $430 million and $450 million in the fourth quarter. The biopharmaceutical company expects its expenditure in the fourth quarter to narrow to between $438 million and $400 million from previous guidance of between $400 and $420 million.
The acquisition of Dallas-based CerSci marked an important milestone in the company’s evolution. With the acquisition of the clinical-stage biotechnology company, the company gains access to a portfolio of novel compounds for neurological conditions. For starters, CerSci therapeutics expands and strengthens Acadia Pharmaceuticals on the development of non-opioid therapies for acute and chronic pain.
Acadia has outperformed the market this year as it is already up by more than 15% for the year. Given the solid underlying fundamentals, the stock could make a run for its all-time high.